{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T19:58:26Z","timestamp":1793303906209,"version":"4.5.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2024,11,6]],"date-time":"2024-11-06T00:00:00Z","timestamp":1730851200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,11,6]],"date-time":"2024-11-06T00:00:00Z","timestamp":1730851200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000050","name":"U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["1ZIAHL006163"],"award-info":[{"award-number":["1ZIAHL006163"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"name":"FNIH Biomarkers Consortium project MRD in AML"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bone Marrow Transplant"],"published-print":{"date-parts":[[2025,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Measurable residual disease (MRD) in adults with acute myeloid leukemia (AML) in complete remission is an important prognostic marker, but detection methodology requires optimization. Persistence of mutated <jats:italic>NPM1<\/jats:italic> or <jats:italic>FLT3<\/jats:italic>-ITD in the blood of adult patients with AML in first complete remission (CR1) prior to allogeneic hematopoietic cell transplant (alloHCT) associates with increased relapse and death after transplant. The prognostic implications of persistence of other common AML-associated mutations, such as <jats:italic>IDH1<\/jats:italic>, at this treatment landmark however remain incompletely defined. We performed testing for residual <jats:italic>IDH1<\/jats:italic> variants (<jats:italic>IDH1<\/jats:italic>m) in pre-transplant CR1 blood of 148 adult patients undergoing alloHCT for <jats:italic>IDH1<\/jats:italic>-mutated AML at a CIBMTR reporting site between 2013 and 2019. No statistically significant post-transplant differences were observed between those testing <jats:italic>IDH1<\/jats:italic>m positive (<jats:italic>n<\/jats:italic>\u2009=\u200953, 36%) and negative pre-transplant (overall survival (OS): <jats:italic>p<\/jats:italic>\u2009=\u20090.4; relapse: <jats:italic>p<\/jats:italic>\u2009=\u20090.5). For patients with <jats:italic>IDH1<\/jats:italic> mutated AML co-mutated with <jats:italic>NPM1<\/jats:italic> and\/or <jats:italic>FLT3<\/jats:italic>-ITD, only detection of persistent mutated <jats:italic>NPM1<\/jats:italic> and\/or <jats:italic>FLT3<\/jats:italic>-ITD was associated with significantly higher rates of relapse (<jats:italic>p<\/jats:italic>\u2009=\u20090.01). These data, from the largest study to date, do not support the detection of <jats:italic>IDH1<\/jats:italic> mutation in CR1 blood prior to alloHCT as evidence of AML MRD for increased post-transplant relapse risk.<\/jats:p>","DOI":"10.1038\/s41409-024-02447-4","type":"journal-article","created":{"date-parts":[[2024,11,6]],"date-time":"2024-11-06T17:03:39Z","timestamp":1730912619000},"page":"154-160","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Measurable residual mutated IDH1 before allogeneic transplant for acute myeloid leukemia"],"prefix":"10.1038","volume":"60","author":[{"given":"Gege","family":"Gui","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2550-493X","authenticated-orcid":false,"given":"Niveditha","family":"Ravindra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pranay S.","family":"Hegde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgia","family":"Andrew","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Devdeep","family":"Mukherjee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6006-1233","authenticated-orcid":false,"given":"Zo\u00eb","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1515-2141","authenticated-orcid":false,"given":"Jeffery J.","family":"Auletta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Firas","family":"El Chaer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evan C.","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9554-1058","authenticated-orcid":false,"given":"Yi-Bin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Corner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7731-759X","authenticated-orcid":false,"given":"Steven M.","family":"Devine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunil G.","family":"Iyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2817-6836","authenticated-orcid":false,"given":"Antonio Martin","family":"Jimenez Jimenez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8568-4522","authenticated-orcid":false,"given":"Marcos J. G.","family":"De Lima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9816-6302","authenticated-orcid":false,"given":"Mark R.","family":"Litzow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8607-9404","authenticated-orcid":false,"given":"Partow","family":"Kebriaei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wael","family":"Saber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7271-8252","authenticated-orcid":false,"given":"Stephen R.","family":"Spellman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott L.","family":"Zeger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristin M.","family":"Page","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4877-9354","authenticated-orcid":false,"given":"Laura W.","family":"Dillon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher S.","family":"Hourigan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,11,6]]},"reference":[{"key":"2447_CR1","doi-asserted-by":"publisher","first-page":"2753","DOI":"10.1182\/blood.2021013626","volume":"138","author":"M Heuser","year":"2021","unstructured":"Heuser M, Freeman SD, Ossenkoppele GJ, Buccisano F, Hourigan CS, Ngai LL, et al. 2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party. Blood. 2021;138:2753\u201367. https:\/\/doi.org\/10.1182\/blood.2021013626.","journal-title":"Blood"},{"key":"2447_CR2","doi-asserted-by":"publisher","first-page":"1890","DOI":"10.1001\/jamaoncol.2020.4600","volume":"6","author":"NJ Short","year":"2020","unstructured":"Short NJ, Zhou S, Fu C, Berry DA, Walter RB, Freeman SD, et al. Association of measurable residual disease with survival outcomes in patients with acute myeloid leukemia: a systematic review and meta-analysis. JAMA Oncol. 2020;6:1890\u20139. https:\/\/doi.org\/10.1001\/jamaoncol.2020.4600.","journal-title":"JAMA Oncol"},{"key":"2447_CR3","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1182\/hematology.2022000323","volume":"2022","author":"CS Hourigan","year":"2022","unstructured":"Hourigan CS. Achieving MRD negativity in AML: how important is this and how do we get there? Hematol Am Soc Hematol Educ Program. 2022;2022:9\u201314. https:\/\/doi.org\/10.1182\/hematology.2022000323.","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"2447_CR4","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1097\/PPO.0000000000000572","volume":"28","author":"G Gui","year":"2022","unstructured":"Gui G, Hourigan CS. Measurable residual disease assessment as a surrogate marker in new drug development in acute myeloid leukemia. Cancer J. 2022;28:73\u201377. https:\/\/doi.org\/10.1097\/PPO.0000000000000572.","journal-title":"Cancer J"},{"key":"2447_CR5","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1182\/blood-2017-09-801498","volume":"131","author":"GJ Schuurhuis","year":"2018","unstructured":"Schuurhuis GJ, Heuser M, Freeman S, Bene MC, Buccisano F, Cloos J, et al. Minimal\/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party. Blood. 2018;131:1275\u201391. https:\/\/doi.org\/10.1182\/blood-2017-09-801498.","journal-title":"Blood"},{"key":"2447_CR6","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1111\/bjh.16362","volume":"188","author":"J Ghannam","year":"2020","unstructured":"Ghannam J, Dillon LW, Hourigan CS. Next-generation sequencing for measurable residual disease detection in acute myeloid leukaemia. Br J Haematol. 2020;188:77\u201385. https:\/\/doi.org\/10.1111\/bjh.16362.","journal-title":"Br J Haematol"},{"key":"2447_CR7","doi-asserted-by":"publisher","first-page":"1482","DOI":"10.1038\/leu.2017.113","volume":"31","author":"CS Hourigan","year":"2017","unstructured":"Hourigan CS, Gale RP, Gormley NJ, Ossenkoppele GJ, Walter RB. Measurable residual disease testing in acute myeloid leukaemia. Leukemia. 2017;31:1482\u201390. https:\/\/doi.org\/10.1038\/leu.2017.113.","journal-title":"Leukemia"},{"key":"2447_CR8","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1038\/s41409-019-0729-4","volume":"55","author":"M Othus","year":"2020","unstructured":"Othus M, Gale RP, Hourigan CS, Walter RB. Statistics and measurable residual disease (MRD) testing: uses and abuses in hematopoietic cell transplantation. Bone Marrow Transplant. 2020;55:843\u201350. https:\/\/doi.org\/10.1038\/s41409-019-0729-4.","journal-title":"Bone Marrow Transplant"},{"key":"2447_CR9","doi-asserted-by":"publisher","first-page":"2810","DOI":"10.3324\/haematol.2022.282034","volume":"107","author":"JS Blachly","year":"2022","unstructured":"Blachly JS, Walter RB, Hourigan CS. The present and future of measurable residual disease testing in acute myeloid leukemia. Haematologica. 2022;107:2810\u201322. https:\/\/doi.org\/10.3324\/haematol.2022.282034.","journal-title":"Haematologica"},{"key":"2447_CR10","doi-asserted-by":"publisher","unstructured":"Roloff GW, Lai C, Hourigan CS, Dillon LW. Technical advances in the measurement of residual disease in acute myeloid leukemia. J Clin Med. 2017; 6:87. https:\/\/doi.org\/10.3390\/jcm6090087.","DOI":"10.3390\/jcm6090087"},{"key":"2447_CR11","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1182\/hematology.2019000060","volume":"2019","author":"SD Freeman","year":"2019","unstructured":"Freeman SD, Hourigan CS. MRD evaluation of AML in clinical practice: are we there yet? Hematol Am Soc Hematol Educ Program. 2019;2019:557\u201369. https:\/\/doi.org\/10.1182\/hematology.2019000060.","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"2447_CR12","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1001\/jama.2023.1363","volume":"329","author":"LW Dillon","year":"2023","unstructured":"Dillon LW, Gui G, Page KM, Ravindra N, Wong ZC, Andrew G, et al. DNA sequencing to detect residual disease in adults with acute myeloid leukemia prior to hematopoietic cell transplant. JAMA. 2023;329:745\u201355. https:\/\/doi.org\/10.1001\/jama.2023.1363.","journal-title":"JAMA"},{"key":"2447_CR13","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1001\/jama.2023.8653","volume":"330","author":"G Gui","year":"2023","unstructured":"Gui G, Dillon LW, Hourigan CS. DNA sequencing in adults with acute myeloid leukemia to detect residual disease prior to hematopoietic cell transplant-reply. JAMA. 2023;330:190\u20131. https:\/\/doi.org\/10.1001\/jama.2023.8653.","journal-title":"JAMA"},{"key":"2447_CR14","doi-asserted-by":"publisher","unstructured":"Dillon LW, Gui G, Ravindra N, Andrew G, Mukherjee D, Wong ZC, et al. Measurable residual FLT3 internal tandem duplication before allogeneic transplant for acute myeloid leukemia. JAMA Oncol. 2024;10:1104\u201310. https:\/\/doi.org\/10.1001\/jamaoncol.2024.0985.","DOI":"10.1001\/jamaoncol.2024.0985"},{"key":"2447_CR15","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1038\/s41586-018-0623-z","volume":"562","author":"JW Tyner","year":"2018","unstructured":"Tyner JW, Tognon CE, Bottomly D, Wilmot B, Kurtz SE, Savage SL, et al. Functional genomic landscape of acute myeloid leukaemia. Nature. 2018;562:526\u201331. https:\/\/doi.org\/10.1038\/s41586-018-0623-z.","journal-title":"Nature"},{"key":"2447_CR16","doi-asserted-by":"publisher","first-page":"2827","DOI":"10.1182\/blood.2020010165","volume":"137","author":"M Duchmann","year":"2021","unstructured":"Duchmann M, Micol JB, Duployez N, Raffoux E, Thomas X, Marolleau JP, et al. Prognostic significance of concurrent gene mutations in intensively treated patients with IDH-mutated AML: an ALFA study. Blood. 2021;137:2827\u201337. https:\/\/doi.org\/10.1182\/blood.2020010165.","journal-title":"Blood"},{"key":"2447_CR17","doi-asserted-by":"publisher","first-page":"1394","DOI":"10.1182\/bloodadvances.2021004934","volume":"6","author":"JM Middeke","year":"2022","unstructured":"Middeke JM, Metzeler KH, Rollig C, Kramer M, Eckardt JN, Stasik S, et al. Differential impact of IDH1\/2 mutational subclasses on outcome in adult AML: results from a large multicenter study. Blood Adv. 2022;6:1394\u2013405. https:\/\/doi.org\/10.1182\/bloodadvances.2021004934.","journal-title":"Blood Adv"},{"key":"2447_CR18","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1038\/s41375-018-0026-z","volume":"32","author":"M Meggendorfer","year":"2018","unstructured":"Meggendorfer M, Cappelli LV, Walter W, Haferlach C, Kern W, Falini B, et al. IDH1R132, IDH2R140, and IDH2R172 in AML: different genetic landscapes correlate with outcome and may influence targeted treatment strategies. Leukemia. 2018;32:1249\u201353. https:\/\/doi.org\/10.1038\/s41375-018-0026-z.","journal-title":"Leukemia"},{"key":"2447_CR19","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1182\/blood-2016-01-693879","volume":"128","author":"KH Metzeler","year":"2016","unstructured":"Metzeler KH, Herold T, Rothenberg-Thurley M, Amler S, Sauerland MC, Gorlich D, et al. Spectrum and prognostic relevance of driver gene mutations in acute myeloid leukemia. Blood. 2016;128:686\u201398. https:\/\/doi.org\/10.1182\/blood-2016-01-693879.","journal-title":"Blood"},{"key":"2447_CR20","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1186\/s13045-022-01339-8","volume":"15","author":"D Kunadt","year":"2022","unstructured":"Kunadt D, Stasik S, Metzeler KH, Rollig C, Schliemann C, Greif PA, et al. Impact of IDH1 and IDH2 mutational subgroups in AML patients after allogeneic stem cell transplantation. J Hematol Oncol. 2022;15:126 https:\/\/doi.org\/10.1186\/s13045-022-01339-8.","journal-title":"J Hematol Oncol"},{"key":"2447_CR21","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1038\/s41409-023-02189-9","volume":"59","author":"N Ravindra","year":"2024","unstructured":"Ravindra N, Dillon LW, Gui G, Smith M, Gondek LP, Jones RJ, et al. Persistent IDH mutations are not associated with increased relapse or death in patients with IDH-mutated acute myeloid leukemia undergoing allogeneic hematopoietic cell transplant with post-transplant cyclophosphamide. Bone Marrow Transplant. 2024;59:428\u201330. https:\/\/doi.org\/10.1038\/s41409-023-02189-9.","journal-title":"Bone Marrow Transplant"},{"key":"2447_CR22","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1056\/NEJMoa2117344","volume":"386","author":"P Montesinos","year":"2022","unstructured":"Montesinos P, Recher C, Vives S, Zarzycka E, Wang J, Bertani G, et al. Ivosidenib and azacitidine in IDH1-mutated acute myeloid leukemia. N Engl J Med. 2022;386:1519\u201331. https:\/\/doi.org\/10.1056\/NEJMoa2117344.","journal-title":"N Engl J Med"},{"key":"2447_CR23","doi-asserted-by":"publisher","first-page":"2386","DOI":"10.1056\/NEJMoa1716984","volume":"378","author":"CD DiNardo","year":"2018","unstructured":"DiNardo CD, Stein EM, de Botton S, Roboz GJ, Altman JK, Mims AS, et al. Durable remissions with ivosidenib in IDH1-mutated relapsed or refractory AML. N Engl J Med. 2018;378:2386\u201398. https:\/\/doi.org\/10.1056\/NEJMoa1716984.","journal-title":"N Engl J Med"},{"key":"2447_CR24","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.1182\/bloodadvances.2020001503","volume":"4","author":"S Choe","year":"2020","unstructured":"Choe S, Wang H, DiNardo CD, Stein EM, de Botton S, Roboz GJ, et al. Molecular mechanisms mediating relapse following ivosidenib monotherapy in IDH1-mutant relapsed or refractory AML. Blood Adv. 2020;4:1894\u2013905. https:\/\/doi.org\/10.1182\/bloodadvances.2020001503.","journal-title":"Blood Adv"},{"key":"2447_CR25","doi-asserted-by":"publisher","first-page":"2034","DOI":"10.1158\/1078-0432.CCR-23-0182","volume":"29","author":"AT Fathi","year":"2023","unstructured":"Fathi AT, Kim HT, Soiffer RJ, Levis MJ, Li S, Kim AS, et al. Multicenter Phase I Trial Of Ivosidenib As Maintenance Treatment Following Allogeneic Hematopoietic Cell Transplantation for IDH1-mutated acute myeloid leukemia. Clin Cancer Res. 2023;29:2034\u201342. https:\/\/doi.org\/10.1158\/1078-0432.CCR-23-0182.","journal-title":"Clin Cancer Res"},{"key":"2447_CR26","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1182\/bloodadvances.2021005789","volume":"7","author":"M Bill","year":"2023","unstructured":"Bill M, Jentzsch M, Bischof L, Kohlschmidt J, Grimm J, Schmalbrock LK, et al. Impact of IDH1 and IDH2 mutation detection at diagnosis and in remission in patients with AML receiving allogeneic transplantation. Blood Adv. 2023;7:436\u201344. https:\/\/doi.org\/10.1182\/bloodadvances.2021005789.","journal-title":"Blood Adv"},{"key":"2447_CR27","doi-asserted-by":"publisher","first-page":"305","DOI":"10.3324\/haematol.2018.191148","volume":"104","author":"CY Ok","year":"2019","unstructured":"Ok CY, Loghavi S, Sui D, Wei P, Kanagal-Shamanna R, Yin CC, et al. Persistent IDH1\/2 mutations in remission can predict relapse in patients with acute myeloid leukemia. Haematologica. 2019;104:305\u201311. https:\/\/doi.org\/10.3324\/haematol.2018.191148.","journal-title":"Haematologica"},{"key":"2447_CR28","doi-asserted-by":"publisher","first-page":"3205","DOI":"10.1158\/1078-0432.CCR-18-3749","volume":"25","author":"KJ Norsworthy","year":"2019","unstructured":"Norsworthy KJ, Luo L, Hsu V, Gudi R, Dorff SE, Przepiorka D, et al. FDA approval summary: ivosidenib for relapsed or refractory acute myeloid leukemia with an isocitrate dehydrogenase-1 mutation. Clin Cancer Res. 2019;25:3205\u20139. https:\/\/doi.org\/10.1158\/1078-0432.CCR-18-3749.","journal-title":"Clin Cancer Res"},{"key":"2447_CR29","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1159\/000535463","volume":"147","author":"AL Blackmon","year":"2024","unstructured":"Blackmon AL, Hourigan CS. Test then erase? current status and future opportunities for measurable residual disease testing in acute myeloid leukemia. Acta Haematol. 2024;147:133\u201346. https:\/\/doi.org\/10.1159\/000535463.","journal-title":"Acta Haematol"},{"key":"2447_CR30","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/j.bbmt.2013.11.017","volume":"20","author":"CS Hourigan","year":"2014","unstructured":"Hourigan CS, McCarthy P, de Lima M. Back to the future! the evolving role of maintenance therapy after hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2014;20:154\u201363. https:\/\/doi.org\/10.1016\/j.bbmt.2013.11.017.","journal-title":"Biol Blood Marrow Transplant"},{"key":"2447_CR31","doi-asserted-by":"publisher","first-page":"2209","DOI":"10.1056\/NEJMoa1516192","volume":"374","author":"E Papaemmanuil","year":"2016","unstructured":"Papaemmanuil E, Gerstung M, Bullinger L, Gaidzik VI, Paschka P, Roberts ND, et al. Genomic classification and prognosis in acute myeloid leukemia. N Engl J Med. 2016;374:2209\u201321. https:\/\/doi.org\/10.1056\/NEJMoa1516192.","journal-title":"N Engl J Med"},{"key":"2447_CR32","doi-asserted-by":"publisher","first-page":"2059","DOI":"10.1056\/NEJMoa1301689","volume":"368","author":"N Cancer Genome Atlas Research","year":"2013","unstructured":"Cancer Genome Atlas Research N, Ley TJ, Miller C, Ding L, Raphael BJ, Mungall AJ, et al. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N Engl J Med. 2013;368:2059\u201374. https:\/\/doi.org\/10.1056\/NEJMoa1301689.","journal-title":"N Engl J Med"},{"key":"2447_CR33","doi-asserted-by":"publisher","first-page":"865","DOI":"10.3324\/haematol.2016.159343","volume":"102","author":"SA Buckley","year":"2017","unstructured":"Buckley SA, Wood BL, Othus M, Hourigan CS, Ustun C, Linden MA, et al. Minimal residual disease prior to allogeneic hematopoietic cell transplantation in acute myeloid leukemia: a meta-analysis. Haematologica. 2017;102:865\u201373. https:\/\/doi.org\/10.3324\/haematol.2016.159343.","journal-title":"Haematologica"},{"key":"2447_CR34","doi-asserted-by":"publisher","first-page":"2817","DOI":"10.1038\/s41375-022-01692-0","volume":"36","author":"NJ Short","year":"2022","unstructured":"Short NJ, Fu C, Berry DA, Walter RB, Freeman SD, Hourigan CS, et al. Association of hematologic response and assay sensitivity on the prognostic impact of measurable residual disease in acute myeloid leukemia: a systematic review and meta-analysis. Leukemia. 2022;36:2817\u201326. https:\/\/doi.org\/10.1038\/s41375-022-01692-0.","journal-title":"Leukemia"},{"key":"2447_CR35","doi-asserted-by":"publisher","unstructured":"Hegde PS, Andrew G, Gui G, Ravindra N, Mukherjee D, Wong ZC, et al. Measurable residual FLT3 tyrosine kinase domain mutations before allogeneic transplant for acute myeloid leukemia. 2024. https:\/\/doi.org\/10.1038\/s41409-024-02444-7.","DOI":"10.1038\/s41409-024-02444-7"},{"key":"2447_CR36","doi-asserted-by":"publisher","unstructured":"Gui G, Ravindra N, Hegde PS, Andrew G, Mukherjee D, Wong Z, et al. Measurable residual mutated IDH2 before allogeneic transplant for acute myeloid leukemia. Bone Marrow Transplant. 2024. https:\/\/doi.org\/10.1038\/s41409-024-02449-2.","DOI":"10.1038\/s41409-024-02449-2"},{"key":"2447_CR37","doi-asserted-by":"publisher","first-page":"1617","DOI":"10.1056\/NEJMoa040465","volume":"350","author":"PJ Valk","year":"2004","unstructured":"Valk PJ, Verhaak RG, Beijen MA, Erpelinck CA, Barjesteh van Waalwijk van Doorn-Khosrovani S, Boer JM, et al. Prognostically useful gene-expression profiles in acute myeloid leukemia. N Engl J Med. 2004;350:1617\u201328. https:\/\/doi.org\/10.1056\/NEJMoa040465.","journal-title":"N Engl J Med"},{"key":"2447_CR38","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1200\/JCO.19.03011","volume":"38","author":"CS Hourigan","year":"2020","unstructured":"Hourigan CS, Dillon LW, Gui G, Logan BR, Fei M, Ghannam J, et al. Impact of conditioning intensity of allogeneic transplantation for acute myeloid leukemia with genomic evidence of residual disease. J Clin Oncol. 2020;38:1273\u201383. https:\/\/doi.org\/10.1200\/JCO.19.03011.","journal-title":"J Clin Oncol"},{"key":"2447_CR39","doi-asserted-by":"publisher","first-page":"2813","DOI":"10.1182\/blood.2022017808","volume":"141","author":"F El Chaer","year":"2023","unstructured":"El Chaer F, Hourigan CS, Zeidan AM. How I treat AML incorporating the updated classifications and guidelines. Blood. 2023;141:2813\u201323. https:\/\/doi.org\/10.1182\/blood.2022017808.","journal-title":"Blood"}],"container-title":["Bone Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41409-024-02447-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41409-024-02447-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41409-024-02447-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,10]],"date-time":"2025-02-10T13:36:37Z","timestamp":1739194597000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41409-024-02447-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,6]]},"references-count":39,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["2447"],"URL":"https:\/\/doi.org\/10.1038\/s41409-024-02447-4","relation":{},"ISSN":["0268-3369","1476-5365"],"issn-type":[{"value":"0268-3369","type":"print"},{"value":"1476-5365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,6]]},"assertion":[{"value":"23 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 October 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 October 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 November 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"CSH: The National Heart, Lung, and Blood Institute receives research funding for the laboratory of CSH from the Foundation of the NIH AML MRD Biomarkers Consortium. JJA: Advisory Committee: AscellaHealth and Takeda. FEC: Consultant: SPD Oncology, Amgen, Association of Community Cancer Centers; Clinical Trial Grant Support (PI) to the University of Virginia: Amgen, BMS, Celgene, SPD Oncology, Sanofi, Bristol Myers Squibb, FibroGen, PharmaEssentia, BioSight, MEI Pharma, Novartis, Arog pharmaceuticals; Travel grant: DAVA Oncology. ECC: Consultant: Rigel Pharmaceuticals and AbbVie. YBC: Consultant: Incyte, Takeda, Astellas, Editas, Novo Nordisk, Pharmacosmos, Vor. AC: Employment: Bio-Rad Laboratories. AMJJ: Funding: Abbvie. MJGDL: Advisory Board: Pfizer, Bristol Myers Squibb; Data Safety Monitoring Board: Novartis, Abbvie; Research Funding: Miltenyi Biotec. MRL: Research support: Abbvie, Astellas, Amgen, Actinium, Pluristem, Sanofi; Speakers Bureau: Beigene, Amgen; Data Safety Monitoring Committee: Biosight. PK: Consultant: Pfizer, Jazz Pharmaceuticals","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Protected health information for research was collected and maintained in CIBMTR\u2019s capacity as a public health authority under the Health Insurance Portability and Accountability Act (HIPAA) privacy rule. All patients provided written informed consent for participation in the National Marrow Donor Program institutional review board\u2013approved CIBMTR database (NCT01166009) and repository (NCT04920474) research protocols. Research was performed in compliance with all applicable federal regulations pertaining to the protection of human research participants and with the approval of the CIBMTR observational research group.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}]}}